Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2 ovvorobeva@mail.ru
Список исп. литературыСкрыть список 1. Gorwood Ph. Neurobiological mechanisms of anhedonia. Dialog Clin Neurosci 2008; 10 (3): 291–9. 2. Lim BK, Huang KW, Grueter BA et al. Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens. Nature 2012; 487: 183–9. DOI: 10.1038/nature11160 3. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29 (10): 1765–81. 4. Vorob’eva O.V. Valdoxan in the Treatment of Depression in Neurological Practice: Results of the Russian Multicenter Naturalistic Study “Resonance”. Neurosci Behav Physiol 2013; 43 (9): 1126–31. 5. World Health Organization. ICD 10 the ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, 1992. 6. Mykletun A, Stordal E, Dahl AA. Hospital Anxiety and Depression (HAD) Scale: Factor structure, item analyses and internal consistency in a large population. Br J Psychiatry 2001; 179: 540–4. 7. Denollet J, Pedersen SS, Daemen J et al. Reduced positive affect (anhedonia) predicts major clinical events following implantation of coronary-artery stents. J Intern Med 2008; 263: 203–11. DOI: 10.1111/j.1365-2796.2007.01870.x 8. Kessing D, Pelle AJ, Kupper N et al. Positive affect, anhedonia, and compliance with self-care in patientswith chronic heart failure. J Psychosom Res 2014; 77: 296–301. DOI: 10.1016/j.jpsychores.2014.08.007 9. Loo H, Hale A, D’Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2c antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239–47.